Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis
Annals of Epidemiology, ISSN: 1047-2797, Vol: 24, Issue: 4, Page: 279-285
2014
- 58Citations
- 57Captures
- 2Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations58
- Citation Indexes58
- 58
- CrossRef47
- Captures57
- Readers57
- 57
- Mentions2
- News Mentions1
- 1
- References1
- 1
Most Recent News
Post-COVID-19 bifacial weakness and paraesthesia: a case report
Johann Stubya, René Rotha, Nico Streckerb, Jonas Teubnerb, Alain Rudigera a Internal Medicine, Limmattal Hospital Zurich, Schlieren, Switzerland b Neurology, Limmattal Hospital Zurich, Schlieren, Switzerland
Article Description
Peripheral neuropathy (PN) is an identified risk of systemic antibacterial therapy with fluoroquinolones. The risk and its severity, including the development of Guillain-Barré syndrome (GBS) between individual agents is uncertain. This study examines the association between fluoroquinolones and PN and GBS in cases spontaneously reported to the FDA Adverse Event Reporting System. Cases reported to FDA Adverse Event Reporting System between 1997 and 2012 were retrieved. The Medical Dictionary for Regulatory Activities Preferred Term was used to define PN and GBS. Individual fluoroquinolones were identified by generic names and route of administration. Empirical Bayes Geometric Mean (EBGM) with 95% confidence interval (EB05–EB95) was calculated as disproportionality measure. Safety signals with EB05 2 or more was considered a significant disproportional increase in the event reporting of at least twice times higher than that expected. There were 539 PN reports out of 46,257 adverse event reports submitted for fluoroquinolones. Nine percent of PN reports were for GBS. Significant disproportionality of PN (EBGM 2.70; EB05–EB95 2.51–2.90) and GBS (EBGM 3.22; EB05–EB95 2.55–4.02) was identified for fluoroquinolones. Signals of PN were detected for ciprofloxacin (EBGM 3.24; EB05–EB95 2.87–3.66) and levofloxacin (EBGM 3.36; EB05–EB95 3.02–3.72). A GBS signal was detected for ciprofloxacin (EBGM 4.15; EB05–EB95 2.94–5.74). GBS and PN, respectively, ranked 6th and 8th among reported neurologic events. This study re-emphasizes the link between fluoroquinolones and PN and shows the potential association with more severe forms of nerve damage, for example, GBS. Unless the benefit of fluoroquinolone therapy (e.g., overwhelming infection or development of bacterial resistance) outweighs PN risk, treatment with alternative antibacterial agents is recommended.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1047279713004754; http://dx.doi.org/10.1016/j.annepidem.2013.12.009; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84895455991&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/24472364; https://linkinghub.elsevier.com/retrieve/pii/S1047279713004754; http://www.annalsofepidemiology.org/article/S1047-2797(13)00475-4/abstract; http://linkinghub.elsevier.com/retrieve/pii/S1047279713004754
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know